JP2010507722A - 標的化リガンドを固定化するための改良型リンカー - Google Patents
標的化リガンドを固定化するための改良型リンカー Download PDFInfo
- Publication number
- JP2010507722A JP2010507722A JP2009534770A JP2009534770A JP2010507722A JP 2010507722 A JP2010507722 A JP 2010507722A JP 2009534770 A JP2009534770 A JP 2009534770A JP 2009534770 A JP2009534770 A JP 2009534770A JP 2010507722 A JP2010507722 A JP 2010507722A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- lipid
- agent
- targeting
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008685 targeting Effects 0.000 title claims description 29
- 239000003446 ligand Substances 0.000 title claims description 8
- 230000003100 immobilizing effect Effects 0.000 title description 2
- 150000002632 lipids Chemical class 0.000 claims abstract description 37
- 239000002245 particle Substances 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 239000004094 surface-active agent Substances 0.000 claims description 22
- 239000002502 liposome Substances 0.000 claims description 13
- -1 phosphatidyl lipid Chemical class 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 150000008104 phosphatidylethanolamines Chemical group 0.000 claims description 12
- 239000000693 micelle Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 238000003384 imaging method Methods 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000000839 emulsion Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 239000010410 layer Substances 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 125000005647 linker group Chemical group 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 13
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- VEMHGBRKKQAHQD-UHFFFAOYSA-N n'-(1h-imidazol-2-yl)-n,n-dimethylmethanimidamide Chemical compound CN(C)C=NC1=NC=CN1 VEMHGBRKKQAHQD-UHFFFAOYSA-N 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 0 CC*C(C1=CNc2cc(C3OCCO3)ccc2C1=O)=O Chemical compound CC*C(C1=CNc2cc(C3OCCO3)ccc2C1=O)=O 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 4
- HKYAKZXAOGNRHX-UHFFFAOYSA-N 1-tritylimidazol-2-amine Chemical compound NC1=NC=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HKYAKZXAOGNRHX-UHFFFAOYSA-N 0.000 description 4
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical compound NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 4
- CEMWDKOEAHBYQZ-UHFFFAOYSA-N 2-(3,5-dimethylphenoxy)butanoic acid Chemical compound CCC(C(O)=O)OC1=CC(C)=CC(C)=C1 CEMWDKOEAHBYQZ-UHFFFAOYSA-N 0.000 description 4
- HHNFWIKAGXWBAT-UHFFFAOYSA-N 2-(4-chlorosulfonyl-3,5-dimethylphenoxy)butanoic acid Chemical compound CCC(C(O)=O)OC1=CC(C)=C(S(Cl)(=O)=O)C(C)=C1 HHNFWIKAGXWBAT-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- LYBUMLAYZAGWBQ-UHFFFAOYSA-N diethyl 2-[[3-(1,3-dioxolan-2-yl)anilino]methylidene]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)=CNC1=CC=CC(C2OCCO2)=C1 LYBUMLAYZAGWBQ-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VRGGEVFPRCOISA-UHFFFAOYSA-N 4-[4-[[1-methoxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-1-oxopropan-2-yl]sulfamoyl]-3,5-dimethylphenoxy]butanoic acid Chemical compound CC(C)(C)OC(=O)NCC(C(=O)OC)NS(=O)(=O)C1=C(C)C=C(OCCCC(O)=O)C=C1C VRGGEVFPRCOISA-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- PHHWHEYGTYIHMU-UHFFFAOYSA-N amino propanoate 2,2,2-trifluoroacetic acid Chemical compound CCC(=O)ON.OC(=O)C(F)(F)F PHHWHEYGTYIHMU-UHFFFAOYSA-N 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- MDNGCQNDMUBQNJ-UHFFFAOYSA-N ethyl 7-(1,3-dioxolan-2-yl)-1-methyl-4-oxoquinoline-3-carboxylate Chemical compound C=1C=C2C(=O)C(C(=O)OCC)=CN(C)C2=CC=1C1OCCO1 MDNGCQNDMUBQNJ-UHFFFAOYSA-N 0.000 description 3
- LGUQXDCUJRCTAT-UHFFFAOYSA-N ethyl 7-(1,3-dioxolan-2-yl)-4-oxo-1h-quinoline-3-carboxylate Chemical compound C=1C=C2C(=O)C(C(=O)OCC)=CNC2=CC=1C1OCCO1 LGUQXDCUJRCTAT-UHFFFAOYSA-N 0.000 description 3
- ARCCBDIYMYCXOO-UHFFFAOYSA-N ethyl 7-[[1h-imidazol-2-yl(trityl)amino]methyl]-1-methyl-4-oxoquinoline-3-carboxylate Chemical compound C=1C=C2C(=O)C(C(=O)OCC)=CN(C)C2=CC=1CN(C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=NC=CN1 ARCCBDIYMYCXOO-UHFFFAOYSA-N 0.000 description 3
- SIYKOZISJLPJHT-UHFFFAOYSA-N ethyl 7-formyl-1-methyl-4-oxoquinoline-3-carboxylate Chemical compound O=CC1=CC=C2C(=O)C(C(=O)OCC)=CN(C)C2=C1 SIYKOZISJLPJHT-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 3
- 229960001217 perflubron Drugs 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- QMLKQXIAPAAIEJ-UHFFFAOYSA-N 2-(phenylmethoxycarbonylamino)ethylazanium;chloride Chemical compound Cl.NCCNC(=O)OCC1=CC=CC=C1 QMLKQXIAPAAIEJ-UHFFFAOYSA-N 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- RDWKSTCSXUUWFR-UHFFFAOYSA-N 7-[[1h-imidazol-2-yl(trityl)amino]methyl]-1-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(C)C=C(C(O)=O)C(=O)C2=CC=C1CN(C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=NC=CN1 RDWKSTCSXUUWFR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000002616 MRI contrast agent Substances 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- RVZOIHYDGRMCQC-UHFFFAOYSA-N n,n-dimethyl-n'-(1-tritylimidazol-2-yl)methanimidamide Chemical compound CN(C)C=NC1=NC=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 RVZOIHYDGRMCQC-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- TVSPPYGAFOVROT-UHFFFAOYSA-N 2-phenoxybutanoic acid Chemical compound CCC(C(O)=O)OC1=CC=CC=C1 TVSPPYGAFOVROT-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AVYQPULWSBXEOF-UHFFFAOYSA-N Cc1cc(OCCCC(O)=O)cc(C)c1S(Cl)(=O)=O Chemical compound Cc1cc(OCCCC(O)=O)cc(C)c1S(Cl)(=O)=O AVYQPULWSBXEOF-UHFFFAOYSA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 108700031401 DOTA-Tyr(3)- 90Y-octreotide Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SRIBNOUIYXBOST-UHFFFAOYSA-N [N].NCCO Chemical compound [N].NCCO SRIBNOUIYXBOST-UHFFFAOYSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical group 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GDJLJNFNXINTHS-RGMNGODLSA-N methyl (2s)-2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CNC(=O)OC(C)(C)C GDJLJNFNXINTHS-RGMNGODLSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Acoustics & Sound (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
本願は、2006年10月24日出願の米国仮特許出願第60/853,824号及び2007年10月16日出願の米国特許出願第11/872,984号の利益を主張するものであり、それらの内容は参照により本明細書に組み込まれる。
従って、一態様において、本発明は式
式中、各nは独立して1〜4であり、
xは20〜60の整数であり、
Zは=NH又は=Oであり、
フェニレンは必要に応じて、アルキル、アルケニル又はアルキニルによって置換されていてもよく、
標的化剤は、分子の残りの部分と結合するためのアミノ基又は水酸基を含有する部分であり、及び
アンカーは、化合物を脂質/界面活性剤ベースの粒子状組成物中に包埋するための親油性化合物であり、該アンカーも分子の残りの部分と結合するためのアミノ基又は水酸基を含有する。
特に好ましい本発明の化合物は、式(2)
本発明の乳剤は、本発明の方法において直接調製及び使用してもよく、又は乳剤の成分がキットの形態で供給されてもよい。キットは、全ての所望の補助的物質を緩衝液中に又は凍結乾燥の状態で含有する予め調製された標的化組成物を含んでいてもよい。或いはキットは、別個に供給される、標的リガンドを含まない乳剤を含んでいてもよい。これらの場合、典型的には乳剤はマレイミド基などの反応基をリンカーのうちアンカーの遠位にある末端に有し、それにより乳剤が標的化剤と混合された時に、乳剤自体と標的化剤とを結合させる。結合を生じさせるのに有用な追加的な試薬を別個の容器として提供してもよい。或いは、別個に供給される、反応基を有する所望の成分に結合したリンカーと結合する反応基を乳剤が有していてもよい。適したキットを作成するための、様々な手法を想定することができる。従って、最終的な乳剤を構成する個々の成分は個別の容器で供給されてもよく、又はキットは単に、キットそれ自体とは別個に提供される他の材料と組み合わせるための試薬を含むだけでもよい。
乳剤及びその調製用キットは、高発現レベルの標的を含有する組織の造影、及び、かかる発現レベルの組織が望ましくない場合はその治療を含む、本発明の方法において有用である。
実施例1
式(2)の化合物の調製
αvβ3標的化リガンド中間体12の合成経路:
2−アミノイミダゾールヘミスルフェート(化合物1、30g、227mmol)(アルドリッチ)を水(216mL)に溶解し、炭酸ナトリウム(24.1g、227mmol)を添加した。溶液を室温で15分間撹拌した。水を真空中で除去し、残留物を無水エタノール(85mL)中で粉砕し、混合物をろ過して溶媒を真空中で除去した。残留物を直ちに使用した。
生成物I.D.:1H NMR、FT−IR、LC/MS
粗製2−[(ジメチルアミノ)メチレン]アミノイミダゾール(2)に塩化メチレン(750mL)、トリエチルアミン(98mL、700mmol)及び塩化トリチル(62.98g、226mmol)(アルドリッチ)を添加した。反応混合物を室温で3時間撹拌した。溶媒を真空中で除去し、粗製の化合物3をメタノールから結晶化させた。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS
化合物3(44.64g、117mmol)に、試薬級エタノール(1200mL)、氷酢酸(20.65mL)及びヒドラジン(26mL)を添加した。反応混合物を50℃で5時間撹拌した。溶媒を除去し、粗生成物に塩化メチレン(1,500ml)及び1Nの水酸化ナトリウム(67ml)を室温で15分間撹拌しながら添加した。得られた2つの層を分離して有機層をブライン(2×300mL)で洗浄し、無水硫酸ナトリウムで乾燥させてろ過し、溶媒を真空中で除去して、1−トリチル−2−アミノイミダゾール、化合物4(37.2g、97%)を得た。融点196〜199℃。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR及びLC/MS
化合物5(アルファ・エイサー)と化合物6(アルドリッチ)との混合物を、ディーンスタークトラップが取り付けられた100mLの一口丸底フラスコ中で115℃まで一晩加熱し、その後室温まで放冷した。回転蒸発(1時間/40℃)により残留エタノールのほとんどを除去した。生成物7(20.30g、定量的収率)は濃厚な油であり、これは時間が経ったり、フリーザーに入れたり、又は乳鉢で激しく破砕したりすることで凝固する。分析(1H NMR)により、そのまま次のステップで使用するために十分純度が高いことが確認される。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR
化合物7を、1Lの三口丸底フラスコ中の250℃に予熱された300mLのジフェニルエーテル(アルドリッチ)に添加した。温度を少しの間(1〜2分間)約240℃まで下げ、その後257℃まで上げて255〜260℃で15分間維持し、色が暗くなること、エタノール蒸気の発生を確認した。室温に冷却すると、いくらかの沈殿物が分離したが、混合物は極めて濃かった。混合物をヘキサンで1:4希釈し、さらに沈殿物を分離した。沈殿物をろ過し、ヘキサンで3回洗浄して乾燥させ、19.02gの生成物8(84%)を得た。分析(1H NMR)により、この生成物の純度がそのまま次のステップで使用するのに十分な高さであることが示された。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS
化合物8を、500mLの一口丸底フラスコ中の無水DMF(アルドリッチ)に溶解した。無水炭酸カリウム(EMサイエンス)を添加し、混合物を15分間撹拌した。ヨードメタン(アルドリッチ)を添加した後、混合物を室温で一晩撹拌し、その後濃縮してCH2Cl2と含水チオ硫酸ナトリウムとに分離した。CH2Cl2層をブラインで洗浄し、無水硫酸ナトリウムで乾燥させ、ろ過して濃縮し、19.30gの粗製物9(褐色様の固体)を得た。1H NMRスペクトルは十分なものであったが、TLC(MeOH:DCM 1:9)は、少量のより極性の低い不純物と、いくらかの極性の高い不純物(おそらくは大部分が無機物)を示した。THF/水又はCH2Cl2/ヘキサンからの再沈殿により精製しようとしたが、不十分であった。シリカゲルプラグ(勾配はCH2Cl2中1〜2〜4〜6〜10%メタノール)でのクロマトグラフィーによって精製された生成物(17.93g、収率95%)を得た。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS
化合物9を1Lの一口丸底フラスコ中でアセトン(EMCO)に60℃で溶解した。予め洗浄したアンバーライトIR−120樹脂(アルドリッチ)を水と共に添加し、混合物を60℃で40分間撹拌し、20分(MCLS0995−078−1)及び40分の時点で一定量を取り出した。取り出した部分のHPLC分析から、アルデヒドの脱保護が20分で完了していたことが明らかとなった。混合物を熱浴槽から取り出してろ過し、初期量の約40%になるまで回転蒸発下で濃縮した(アセトンの除去)。得られた含水懸濁液をCH2Cl2と飽和含水重炭酸ナトリウムで分離した。水層を2×CH2Cl2で抽出した。集めた有機層をブラインで洗浄し、無水硫酸ナトリウムで乾燥させ、ろ過して濃縮し、生成物10(4.20g、収率81%)を得た。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS
トルエン中の化合物4及び化合物10を、復水器及びディーンスタークトラップが取り付けられた1Lの一口丸底フラスコ中、窒素下110℃で一晩撹拌した。室温に冷却した後、中間体であるイミン(11)を含有する混合物を濃縮し、分析した(1H NMR、FT−IR、UV)。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、13C NMR、FT−IR、LC/MS、残留溶媒分析、元素分析、乾燥減量
この中間体について作成されたCofA
化合物12をTHFに溶解した。含水LiOHを添加し、混合物を室温で3時間撹拌し、その後水で希釈して、THFが除去されるまで(起泡及び沈殿物の出現)濃縮し、HClでpH4まで酸性化させた(激しい起泡;より多くの沈殿物)。沈殿物を分離し、水で洗浄して乾燥させ、化合物13(生成物、3.40g、HPLC、LC−MSによって純度96.5%、収率81.7%)を得た。1H NMR分析から、遊離アミン型より、過度にプロトン化された種であるTr−Im−N(H2)+−CH2−Arとの整合性が高い。元素分析から、アミン部位のいくつかにおける塩化アルキルアンモニウム塩の部分的な形成が確認される。(材料はステップ17でそのまま使用した)
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS
500mLの三口フラスコに化合物14及びNaOHを窒素パージ下で充填した。機械で撹拌しながら混合物を加熱してフェノールを融解させ、次に100mLのDMSOを添加した。溶液を125℃に加熱し、次に100℃に冷却した。100℃で化合物15(アルドリッチ)を3分間かけて添加し(8℃の発熱)、次に温度を30分間で125℃まで上昇させた。反応物を90℃まで放冷し、100mLのH2Oを添加した。混合物を60℃まで放冷し、18mLの50%NaOH(含水)を70℃まで発熱させながら添加し、その温度で反応物を15分間保持した。反応物を40℃に冷却し、250mLの水を添加した後、pHが8に達するまで濃HClを添加した。反応物を周囲温度まで冷却し、次に4×50mLのMTBEで抽出した。濃HCl(約20mL)を用いて水層を結晶化が始まるpH1まで酸性化させた。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS
500mLの三口フラスコに、3,5−ジメチルフェノキシブタン酸(17)(25g、120mmol)及びCH2Cl2(100mL)を充填した。この溶液を機械により撹拌しながら−27℃まで冷却し、次にクロロスルホン酸(42g、360mmol)を30分間かけて滴下により添加した(温度は最高で−20℃に達した)。材料をさらに1時間、−25℃で撹拌し、次にNaHCO3(20g、238mmol)を反応混合物に添加した。次に反応混合物を150gの氷に添加した。次に反応混合物をEtOAc(750mL)で抽出し、Na2SO4(10g)で乾燥させてろ過し、次に真空中で濃縮した。粗生成物を5℃で2回、MTBEと共に(50mL、次に25mL)粉砕し、20.0gの化合物18(収率54%)を得た。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS
4−(クロロスルホニル)−3,5−ジメチルフェノキシブタン酸、化合物18(2.50g、8.1mmol)のジオキサン(60.0g)溶液を、室温で水(20.0g)中のH−Dap(Boc)−OMe・HCl(化合物19)(1.66g、6.5mmol)(バケム社)とNaHCO3(8.21g、97.7mmol)の混合物に約45分間の時間をかけて滴下により加えた。添加完了2時間後、反応混合物を真空中で濃縮し、次に水及びクエン酸(12.50g、10.0等量)を添加した。粗生成物をEtOAcで抽出し、EtOAc層を水で1回洗浄した。EtOAc層を濃縮し、2.75gの化合物20(化合物19を基準として収率87%、化合物18を基準として収率69%)を得た。
140mLのジオキサン/28mLのH2O中のH−Dap(Boc)−OMe・HCl(化合物19)(8.0g、31.4mmol)とNaHCO3(38.6g、460mmol)とのスラリーを氷浴で5℃まで冷却した。このスラリーに、4−(クロロスルホニル)−3,5−ジメチルフェノキシブタン酸、化合物18(14.0g、46mmol)のジオキサン(140mL)溶液を、75分間の時間をかけて滴下により加えた。さらに2時間後、反応混合物をろ過し、ろ液を真空中で濃縮した。残留物に水を添加し(総量420mL)、次にこれを75mLのMTBEで抽出した。水相を3NのHCl(含水)を用いて酸性(pH=4)にし、次にEtOAc(300mL)で抽出した。EtOAc抽出物をNa2SO4で乾燥させ、ろ過して真空中で濃縮し、10.2gの所望の生成物20(20.9mmol、化合物19を基準として66.5%、化合物18を基準として45%)が残った。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、FT−IR、LC/MS、旋光度、キラルHPLC
氷水浴で冷却したCH2Cl2(150mL)に溶解させた前記反応物からの粗フェノキシブタン酸(化合物20)(2.75g)溶液に、4−メチルモルホリン(0.89g、8.8mmol)を加え、次にトリメチルアセチルクロリド(1.06g、8.8mmol)を添加した。反応混合物を室温まで温めた。1時間後、反応混合物を真空中で濃縮し、DMF(100mL)を添加して、さらにこれを真空中で除去した(反応しなかった一切のトリメチルアセチルクロリド(沸点105〜106℃)を除去するため)。粗生成物をCH2Cl2(150mL)中に再溶解し、DMF中のベンジルN−(2−アミノエチル)カルバメートヒドロクロリド、化合物21(1.52g、6.6mmol)及び4−メチルモルホリン(1.11g、11.0mmol)の溶液を加えた。1時間後、反応混合物を真空中で濃縮し、EtOAcと水で分離した。層の分離後、EtOAc溶液を希NaHCO3及び水で洗浄した。EtOAc溶液を真空中で濃縮し、粗生成物を得た。この物質をクロマトグラフィー(97:3 EtOAc/MeOH)により精製し、2.80gの生成物22を得た。
化合物20(8.20g、16.8mmol)をDMF(70mL、3A分子篩で乾燥)に溶解した。ジイソプロピルエチルアミン(8.68g、67.1mmol)を添加し、混合物を窒素下で撹拌した。混合物を冷水浴中で冷却し、次にHBTU、O−ベンゾトリアゾール−1−イル−N,N,N’,N’−テトラメチルウロニウムヘキサフルオロホスファート(7.64g、20.1mmol)を17℃未満の温度で少しずつ添加した。混合物をさらに20分間撹拌した。DMF(21mL、3A分子篩で乾燥)中のベンジルN−(2−アミノエチル)カルバメートヒドロクロリド、化合物21(4.65g、20.1mmol)の溶液を17℃未満の温度で滴下により添加した。溶液をさらに30分間撹拌し、周囲温度まで温めた。次に反応溶液を60℃、10mbarで蒸発させた。これにより、33.8gの残留物を得た。この残留物をジクロロメタン(120mL)に溶解した。混合物を0.1MのHCl(含水)各20mLで2回洗浄した。次に混合物を10%NaHCO3各20mLで3回洗浄した。50℃、10mbarで蒸発させ、13.8gの残留物を得た。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、13C NMR、FT−IR、LC/MS、残留溶媒分析、元素分析、乾燥減量、旋光度
この中間体について作成されたCofA
化合物22をCH2Cl2:トリフルオロ酢酸に溶解し、室温、窒素下で30分間撹拌し、その後濃縮して6のCH2Cl2を蒸発させ、高真空下で乾燥させて、化合物23(薄黄色の油、3.14g)を得た。これはそのままステップ17で使用した。
プロセス中のアッセイ:HPLC
生成物I.D.:1H NMR、LC/MS、旋光度
ガラス器具を110℃のオーブンで乾燥させて、加熱、窒素下で組み立てた。
窒素雰囲気下、磁気攪拌した、無水N−メチルピロリジノン(50mL)中のジイソプロピルエチルアミン(16.5mL;94.7mmol)中の酸性のスラリー13(5.15g;9.5mmol)をO−ベンゾトリアゾール−1−イル−N,N−N’,N’−テトラメチルウロニウムテトラフルオロボレート(3.65g;11.4mmol)の1分量で処理し、続いて無水NMP(15mL)で処理した。スラリーを窒素下、周囲温度(25℃)で15分間撹拌した。無水NMP(100mL)中、いくらかの残留トリフルオロ酢酸(計算上、約21.9mmol)を含有したアミン23(8.9g;72%アッセイ;9.5mmol)の粗トリフルオロ酢酸塩の溶液を62分間かけて滴下により添加した。このとき温度が25℃から28℃に上昇する少しの発熱を伴った。添加用漏斗を無水NMP(10mL)で洗浄し、反応混合物に添加した。透明で明るい琥珀色の溶液を周囲温度、窒素下(3:55pm)で一晩撹拌した。pH紙を反応混合物に浸漬し、次に水に浸漬すると、pH≧8を示した。
量=9.6g。≧94% アッセイでほんの痕跡量の不純物。
収率=92.9%
2.5LのParrボトル中、Degussa E101 NE/W 10%パラジウム炭素(2.0g)を含有する905mLメタノール中のN−カルボベンゾキシ中間体24(9.05g;8.3mmol)の溶液を水素で6回、加圧及び減圧して、大きいParrシェーカーの残留空気を除去した。ボトルを水素で44.5psigに加圧し、Parr水素化反応器で振盪した。
量=7.75g。≧94% DADによるアッセイ。
収率=97.3%
化合物25、210mg(0.22mmol)を6mLの5:1(v:v)THF/H2Oに溶解した。この溶液に200μLの3N LiOH(含水)を添加し、得られた2相系をアルゴン下、周囲温度で3.5時間撹拌した。3.5時間後、反応混合物のpHを1N HCl(含水)を用いて約6に調整した。反応混合物をアルゴンでパージすることによってTHFを除去し、白色のスラリーを得た(真空中で除去しようとすると、激しく起泡した)。このスラリーに5mLのH2Oを添加し、得られたスラリーを、高純度焼結ガラス漏斗を通じてろ過した(緩速ろ過)。固体を10mLのH2Oで洗浄して空気乾燥させ、134mg(0.14mmol、65%)の化合物26が得られた。
化合物26(132mg、0.14mmol)を5mLのTFA(シグマ−アルドリッチ)に溶解した。この溶液に、アルゴン下、0.5mLのEt3SiH(アルファ・エイサー)を添加した。反応混合物をアルゴン下1時間、70℃に加熱した。次に反応物を周囲温度まで放冷した(反応物から白色固体の沈殿物)。粗反応混合物を0.45ミクロンのシリンジフィルタを通じてろ過した。ろ液に25mLのCH2Cl2を添加し、得られた溶液を真空中35℃で濃縮した。得られた油に2回目の25mLのCH2Cl2を添加し、この溶液を真空中35℃で濃縮した。残留物に25mLのヘキサンを添加し、40℃に加温し、得られた液体層をデカンテーションして取り除き、残留物が残った。2回目の25mLのヘキサンを添加し、上記の手順を繰り返した。残った残留物を真空中40℃で乾燥させ、117mgの化合物27(bis−TFA塩としての生成物を基準に90%)を得た。
1)CHCl3:MeOH 3:1(v:v)−3カラム容量
2)CHCl3:MeOH:H2O 75:24:1(v:v:v)−4カラム容量
3)CHCl3:MeOH:H2O 75:23:2(v:v:v)−4カラム容量
4)CHCl3:MeOH:H2O 75:22:3(v:v:v)−4カラム容量
Claims (13)
- 前記標的化剤がインテグリンを標的とする、請求項1に記載の化合物。
- 前記標的化剤が抗体又はその免疫反応性断片であるか、又は、前記標的化剤が受容体のリガンドである、請求項1に記載の化合物。
- 前記アンカーがホスファチジル脂質の残基である、請求項1に記載の化合物。
- 前記アンカーがホスファチジルエタノールアミン基である、請求項4に記載の化合物。
- xが40〜50の整数である、請求項1に記載の化合物。
- 多数の請求項1に記載の化合物の分子を含む、脂質ベースの粒子製剤。
- 前記粒子が治療剤又は診断剤をさらに含んでなる、請求項7に記載の製剤。
- 前記治療剤が医薬であり、及び/又は
前記診断剤がMRI造影用のキレート化金属であり、又は
前記治療剤若しくは診断剤が放射性核種である、請求項8に記載の粒子製剤。 - 前記脂質ベースの粒子が、リポソーム、ミセル、又は脂質/界面活性剤で被膜された液体フッ化炭素からなるコアを含有するナノ粒子である、請求項8に記載の粒子製剤。
- 前記脂質ベースの粒子が、脂質/界面活性剤で被膜された液体フッ化炭素からなるコアを含有するナノ粒子である、請求項10に記載の粒子製剤。
- 対象における所望の目標箇所を標的化する方法であって、請求項8に記載の製剤を前記対象に投与することを含む方法。
- 対象における所望の目標箇所を標的化する方法における請求項8に記載の製剤の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85382406P | 2006-10-24 | 2006-10-24 | |
US60/853,824 | 2006-10-24 | ||
US11/872,984 | 2007-10-16 | ||
US11/872,984 US7998462B2 (en) | 2006-10-24 | 2007-10-16 | Linkers for anchoring targeting ligands |
PCT/US2007/081540 WO2008070291A2 (en) | 2006-10-24 | 2007-10-16 | Improved linkers for anchoring targeting ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010507722A true JP2010507722A (ja) | 2010-03-11 |
JP5271912B2 JP5271912B2 (ja) | 2013-08-21 |
Family
ID=39492914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009534770A Expired - Fee Related JP5271912B2 (ja) | 2006-10-24 | 2007-10-16 | 標的化リガンドを固定化するための改良型リンカー |
Country Status (6)
Country | Link |
---|---|
US (1) | US7998462B2 (ja) |
EP (1) | EP2094311A4 (ja) |
JP (1) | JP5271912B2 (ja) |
AU (1) | AU2007329793B2 (ja) |
CA (1) | CA2667209A1 (ja) |
WO (1) | WO2008070291A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014148378A1 (ja) * | 2013-03-19 | 2014-09-25 | 公立大学法人首都大学東京 | 界面活性剤様化合物 |
JPWO2016148125A1 (ja) * | 2015-03-16 | 2017-07-13 | 国立大学法人大阪大学 | 新規蛍光標識スフィンゴミエリン及びその利用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100291013A1 (en) * | 2009-05-18 | 2010-11-18 | L'oreal | Comfortable, transfer-resistant colored compositions |
WO2014080251A1 (en) * | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
DK3122757T3 (da) * | 2014-02-28 | 2023-10-09 | Hangzhou Dac Biotech Co Ltd | Ladede linkere og anvendelse deraf til konjugering |
JP6733993B2 (ja) | 2014-10-03 | 2020-08-05 | シンアフィックス ビー.ブイ. | スルファミドリンカー、スルファミドリンカーのコンジュゲート、及び調製の方法 |
CN108026123B (zh) * | 2015-06-15 | 2021-02-05 | 杭州多禧生物科技有限公司 | 用于偶联的亲水链接体 |
EP3413922A1 (en) | 2016-02-08 | 2018-12-19 | SynAffix B.V. | Improved sulfamide linkers for use in bioconjugates |
EP3413915A1 (en) | 2016-02-08 | 2018-12-19 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugates |
JP2019507741A (ja) | 2016-02-08 | 2019-03-22 | シンアフィックス ビー.ブイ. | 治療において使用するためのスルファミドリンカーを含むバイオコンジュゲート |
CN108883191B (zh) | 2016-02-08 | 2022-10-14 | 西纳福克斯股份有限公司 | 用于靶向cd30肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法 |
WO2017137457A1 (en) | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
WO2019185586A1 (en) | 2018-03-26 | 2019-10-03 | Universidad Complutense De Madrid | Ligands for enhanced imaging and drug delivery to neuroblastoma cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532440A (ja) * | 1998-12-18 | 2002-10-02 | デュポン ファーマシューティカルズ カンパニー | ビトロネクチン受容体拮抗剤薬剤 |
JP2005525319A (ja) * | 2002-01-24 | 2005-08-25 | バーンズ−ジューイッシュ ホスピタル | インテグリン標的イメージング剤 |
JP2006516993A (ja) * | 2003-01-24 | 2006-07-13 | バーンズ−ジューイッシュ ホスピタル | 親油性キャリアーを伴うキレート剤 |
JP2008502726A (ja) * | 2004-06-09 | 2008-01-31 | ケレオス インコーポレーティッド | キレートモノアミドの親油性誘導体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511649B1 (en) * | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
US6332770B1 (en) * | 1999-06-09 | 2001-12-25 | Husky Injection Molding Systems, Ltd. | Apparatus for localized preform cooling outside the mold |
WO2002036073A2 (en) * | 2000-11-02 | 2002-05-10 | Smithkline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
WO2007079437A2 (en) * | 2006-01-03 | 2007-07-12 | Kereos, Inc. | Combination antitumor therapies |
-
2007
- 2007-10-16 US US11/872,984 patent/US7998462B2/en not_active Expired - Fee Related
- 2007-10-16 AU AU2007329793A patent/AU2007329793B2/en not_active Ceased
- 2007-10-16 WO PCT/US2007/081540 patent/WO2008070291A2/en active Application Filing
- 2007-10-16 JP JP2009534770A patent/JP5271912B2/ja not_active Expired - Fee Related
- 2007-10-16 EP EP07871170.2A patent/EP2094311A4/en not_active Withdrawn
- 2007-10-16 CA CA002667209A patent/CA2667209A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532440A (ja) * | 1998-12-18 | 2002-10-02 | デュポン ファーマシューティカルズ カンパニー | ビトロネクチン受容体拮抗剤薬剤 |
JP2005525319A (ja) * | 2002-01-24 | 2005-08-25 | バーンズ−ジューイッシュ ホスピタル | インテグリン標的イメージング剤 |
JP2006516993A (ja) * | 2003-01-24 | 2006-07-13 | バーンズ−ジューイッシュ ホスピタル | 親油性キャリアーを伴うキレート剤 |
JP2008502726A (ja) * | 2004-06-09 | 2008-01-31 | ケレオス インコーポレーティッド | キレートモノアミドの親油性誘導体 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014148378A1 (ja) * | 2013-03-19 | 2014-09-25 | 公立大学法人首都大学東京 | 界面活性剤様化合物 |
JPWO2014148378A1 (ja) * | 2013-03-19 | 2017-02-16 | 公立大学法人首都大学東京 | 界面活性剤様化合物 |
JPWO2016148125A1 (ja) * | 2015-03-16 | 2017-07-13 | 国立大学法人大阪大学 | 新規蛍光標識スフィンゴミエリン及びその利用 |
Also Published As
Publication number | Publication date |
---|---|
WO2008070291A3 (en) | 2008-10-23 |
CA2667209A1 (en) | 2008-06-12 |
WO2008070291A2 (en) | 2008-06-12 |
US7998462B2 (en) | 2011-08-16 |
AU2007329793A1 (en) | 2008-06-12 |
EP2094311A4 (en) | 2013-04-10 |
AU2007329793B2 (en) | 2013-01-10 |
JP5271912B2 (ja) | 2013-08-21 |
AU2007329793A2 (en) | 2009-06-04 |
EP2094311A2 (en) | 2009-09-02 |
US20080305037A1 (en) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5271912B2 (ja) | 標的化リガンドを固定化するための改良型リンカー | |
JP3907662B2 (ja) | 自己構築ポリヌクレオチド送達システム | |
Kamaly et al. | Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging | |
JP4057646B2 (ja) | リポソーム剤 | |
US6586559B2 (en) | Polyamide oligomers | |
TW319763B (ja) | ||
JP2744920B2 (ja) | マクロサイクリックキレート薬およびそのキレート | |
EP1885721B1 (fr) | Chelates métalliques de dérivés macrocycliques polyaminocarboxyliques et leur utilisation en imagerie diagnostique | |
JP2000516641A (ja) | 診断および治療用途の目標指向性リポソーム構成物 | |
JP2008515876A (ja) | イメージング及び治療用のイメージング及び治療のエンドキットにおけるシュタウディンガーライゲーションの使用 | |
JPH10152461A (ja) | 新規なカチオン性脂質 | |
EP2076557A1 (en) | Polylysine dendrimer contrast agent | |
JPH09512265A (ja) | コントラスト剤 | |
EP1041976B1 (en) | Polyamide oligomers | |
JP2008502726A (ja) | キレートモノアミドの親油性誘導体 | |
Lin et al. | The development of tertiary amine cationic lipids for safe and efficient siRNA delivery | |
JP2005537266A (ja) | 加水分解性活性物質であるバイオポリマーコンジュゲートを作製するためのイソシアネートリンカーの使用 | |
JP2009501174A (ja) | ペルフルオロアルキル含有錯体、製造方法およびその使用 | |
US20080213181A1 (en) | Preparation of Paramagnetic Nanoparticles Conjugated to Leukotriene B4 (LTB4) Receptor Antagonists, and Their Use as MRI Contrast Agents for the Detection of Infection and Inflammation | |
CN113577303B (zh) | 三分枝rgd修饰的脑胶质瘤靶向脂质材料的制备和应用 | |
JPS6310799A (ja) | プロドラツグ化合物、その製造法およびそれを含有する持続性製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101004 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130409 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130507 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130513 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |